
Kimberly-Clark's "unchanged" outlook now implies 0.7% growth in 2026
Preliminary third-quarter organic sales fell 1.3%. Adjusted EPS of $1.70 beat by about ten cents, driven by tax, interest and equity income while operating profit fell.
Kimberly-Clark says its 2026 outlook is unchanged, but the numbers inside it have shifted. The reaffirmed guide now implies organic sales growth of about 0.7 percent for the year. Organic growth means sales growth before currency swings and deals.
On the morning of 15 October, four Chinese agencies said they had found no formamide in 368 batches of diapers. The same morning Kimberly-Clark said its third-quarter organic sales fell 1.3 percent. The shares rose on an earnings beat, and that beat is weaker than it looks.
The company calls its 2026 outlook consistent with previous expectations, the same wording as in August. The base under the wording has moved. Kimberly-Clark guides organic growth to about 100 basis points, or one percentage point, below the growth of the categories it sells into. The category rate is the number that has changed, so the reaffirmation covers the words, not the arithmetic.
The guidance has stepped down in three stages. In April the company guided organic growth "in line to ahead of" categories that had grown at about 2.5 percent. In August it moved to 100 basis points below a category rate it put at 2 percent. On 15 October the same sentence sits on a category rate of about 1.7 percent.
That formula now returns about 0.7 percent organic growth for the full year. The August arithmetic gave about 1.0 percent, and April gave 2.5 percent or more. Category growth is a trailing twelve-month figure, so a guide set as category minus 100 basis points moves with a number the company does not control.
The 0.7 percent also fixes the fourth quarter. The first three quarters were 2.5, negative 0.1 and negative 1.3 percent, which sum to 1.1 points. A 0.7 percent year is 2.8 points over four quarters. The fourth must therefore come in near 1.7 percent on an equal-weighted approximation, a swing of about three points.
Kimberly-Clark organic sales growth was 2.5 percent in the third quarter of 2025 and 2.5 percent in the first quarter of 2026, then fell to minus 0.1 percent in the second quarter of 2026 and an estimated minus 1.3 percent in the third quarter of 2026.
View data
| Quarter | Organic sales growth, percent |
|---|---|
| Q3 2025 | 2.5 |
| Q4 2025 | 2.1 |
| Q1 2026 | 2.5 |
| Q2 2026 | -0.1 |
| Q3 2026 est. | -1.3 |
The path runs from 2.5 percent to negative 1.3 percent in two quarters. The latest point is a preliminary estimate until the final report. A company that has just lost three points of momentum is guiding to regain most of it in a single quarter. The unchanged wording carries a recovery.
The earnings beat is weaker still. Adjusted earnings per share (earnings with one-time items removed) from continuing operations were $1.70 against $1.45 a year earlier, up 25 cents. Adjusted earnings per share attributable to Kimberly-Clark fell to $1.70 from $1.82 after the IFP deconsolidation, so the beat is a continuing-operations beat only.
Operations added nothing to the increase. Over the same quarter adjusted operating profit fell to $677 million from $683 million, which is worth about minus 2 cents a share.
The reconciliation tables in the 8-K filing supply the rest. Adjusted pre-tax income rose to $632 million from $608 million while operating profit fell. Lower costs below the operating line added roughly 9 cents, consistent with cash of $1,874 million against $617 million a year ago.
The adjusted tax rate dropped to 19.5 percent from 26.5 percent, which is worth about 11 cents. The residual, about $22 million or 7 cents, is equity company income. The four pieces sum to 25 cents.
Against consensus of $1.59, Reuters reported the result as a beat. Net sales of $4.13 billion also topped the analyst average of $4.10 billion. The earnings gain sits entirely below the operating line. A lower tax rate or a larger cash balance has to repeat to count as earnings power.
The $5.37 diluted figure attributable to shareholders carries a $4.33 per share gain on the IFP transaction. It says nothing about the diaper business.
China is the explanation the company offers, and the regulators' finding is real. The joint bulletin covered 168 manufacturers and 180 brands and found no formamide. It said some outside testers had run no blank or parallel samples and had deleted raw data. It names no brand.
The finding removes the allegation. It does not return the shelf space, promotional spending or consumer trust that the false claims cost. Stores rebuild those over quarters, and a bulletin cannot.
The company's own description is "realized and potential" effects of about 100 basis points for the full year. The disruption started in the second quarter, when it cost about 50 basis points. A 100-point full-year drag is 400 points summed over four quarters, so roughly 350 remain for the second half, about 175 a quarter.
On that reading, the third quarter excluding China grew near 0.4 percent. That is still under the 1.7 percent category rate, so China cannot be the whole shortfall.
Margins say the same. The second-quarter adjusted gross margin of 38.8 percent included one-time tariff refunds. The third fell to about 35.5 percent from 36.8 percent a year earlier on the filed figures. A recovering diaper business would not need a lower tax rate to carry its earnings.
The clearing may bring a rebound. The guide already assumes a fourth quarter near 1.7 percent, so a rebound only meets it. The company's own 100-basis-point China allowance leaves the cut to come from the category rate.
If the clearing brings back share, the fourth quarter is the first that can show it. The company will not have that data until after the year ends. The roughly 3 percent premarket rise reads as removal of a tail risk, and it carries no growth signal.
The Kenvue funding is where the weak base matters. Kimberly-Clark has exchange offers open for up to $7.0 billion of Kenvue notes.
The company told Reuters the results open the calendar for debt issuance tied to the deal. New paper sold now rides a share price lifted by a beat built from tax and interest, on a quarter whose organic growth was negative. Waiting for the 5 November final numbers would show whether a 19.5 percent tax rate and equity income repeat.
The 5 November final report will show whether management describes the fourth quarter at about 1.7 percent organic growth. That is the rate the full-year guide now requires after a quarter of minus 1.3. Anything lower turns a 100-basis-point China item into a category problem.